References
- Avanir Pharmaceuticals, Inc. (2013, February). NueDexta® package insert. Aliso Viejo, CA: Author.
- Brooks, B. R., Thisted, R. A., Appel, S. H., Bradley, W. G., Olney, R. K., Berg, J. E. … & AVP-923 ALS Study Group. (2004). Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial. Neurology, 63(8), 1364–1370.
- Choi, D. W. (1987). Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Research, 403(2), 333–336.
- Cruz, M. P. (2013). NueDexta for the treatment of Pseudobulbar Affect: A condition of involuntary crying or laughing. Pharmacy and Therapeutics, 38(6), 325–328.
- Doody, R., Cutler, A., D'Amico, S., Zorowitz, R., Alexander, D., Hammond, F., … & Yonan, C. (2013, January). A study to assess the safety, tolerability, and effectiveness of NueDexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the treatment of Pseudobulbar Affect (PBA)[PRISM II]. Presented at the 164th Annual Meeting of the American Psychiatric Association. May (Vol. 14, p. 18). Retrieved from https://www.bcm.edu/neurology-apps/pdf/poster_00034.pdf
- Messiha, F. S. (1994). Fluoxetine: A spectrum of clinical applications and postulates of underlying mechanisms. Neuroscience & Biobehavioral Reviews, 17(4), 385–396.
- Muller, U., Murai, T., Bauer-Wittmund, T. D., & Von Cramon, Y. (1999). Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury, 13(10), 805–811.
- Panitch, H. S., Thisted, R. A., Smith, R. A., Wynn, D. R., Wymer, J. P., Achiron, A., … & Miller, A. (2006). A randomized, controlled trial of dextromethorphan/quinidine for Pseudobulbar Affect in multiple sclerosis. Annals of Neurology, 59(5), 780–787 doi: 10.1002/ana.20828
- Pattee, G. L., Wymer, J. P., Lomen-Hoerth, C., Appel, S. H., Formella, A. E., & Pope, L. E. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Current Medical Research & Opinion, 30(11), 2255–2265.
- Rosen, H. (2008). Dextromethorphan/quinidine sulfate for pseudobulbar affect. Drugs of Today 44(9), 661. doi: 10.1358/dot.2008.44.9.1258664.
- Schoedel, K. A., Morrow, S. A., & Sellers, E. M. (2014). Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment, 10, 1161–1174. doi: 10.2147/NDT.S30713.
- Seliger, G. M., Hornstein, A., Flax, J., Herbert, J., & Schroeder, K. (1992). Fluoxetine improves emotional incontinence. Brain Injury, 6(3), 267–270.
- Smith, R. A., Berg, J. E., Pope, L. E., Callahan, J. D., Wynn, D., & Thisted, R. A. (2004). Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Multiple Sclerosis, 10(6), 679–685. doi: 10.1191/1352458504ms1106oa.
- Work, S. S., Colamonico, J. A., Bradley, W. G., & Kaye, R. E. (2011). Pseudobulbar affect: An under-recognized and under-treated neurological disorder. Advances in Therapy, 28(7), 586–601.
- Zhang, Y., Britto, M. R., Valderhaug, K. L., Wedlund, P. J., & Smith, R. A. (1992). Dextromethorphan: Enhancing its systemic availability by way of low?dose quinidine?mediated inhibition of cytochrome P4502D6. Clinical Pharmacology & Therapeutics, 51(6), 647–655.